Replies to post #130381 on Biotech Values

[DewDiligence]

What's the earliest date this could be brought to market?

2014, IMO.

Do you think this is efficient use of shareholder funds?

Yes, the cost of funding this phase-3 program is no problem at all for VTRX, and the upside is pretty large if these data can help Incivek retain market share.